15-lipoxygenase metabolite(s) of arachidonic acid mediates adrenocorticotropin action in bovine adrenal steroidogenesis.
The acute activation of adrenal glucocorticoid synthesis by ACTH has long been believed to be mediated by cAMP as the major second messenger, although increases in cellular cAMP concentration have not been observed at low concentrations of ACTH. We found that steroidogenesis in bovine adrenal fasciculata-reticularis cells was activated by the addition of arachidonic acid or its 15-lipoxygenase metabolite, 15-hydroperoxyeicosatetraenoic acid. The cellular 15-lipoxygenase pathway was significantly activated by 1 pM ACTH, at which concentration no increase in cellular cAMP synthesis was observed. The 1 pM ACTH-induced stimulation of steroidogenesis was completely suppressed by a lipoxygenase inhibitor, AA-861. The stimulation was independent of the increase in cellular cAMP. These results show that the action of 1 pM ACTH on steroidogenesis may be mediated by the 15-lipoxygenase metabolite(s) as a solo second messenger. The addition of ACTH at concentrations higher than 10 pM increased both the 15-lipoxygenase activity and cellular cAMP synthesis. Under these conditions, the 15-lipoxygenase metabolite(s) and cAMP were shown to mediate the activation of steroidogenesis synergistically. The presence of a dual second messenger system could explain the stimulation of steroidogenesis by ACTH at physiological concentrations.
Yamazaki
T
T
Faculty of Integrated Arts and Sciences, Hiroshima University, Higashihiroshima 739, Japan.
Higuchi
K
K
Kominami
S
S
Takemori
S
S
D000818:Animals; D001093:Arachidonate 15-Lipoxygenase / Q000378:metabolism*; D001095:Arachidonic Acids / Q000378:metabolism / Q000494:pharmacology*; D016227:Benzoquinones / Q000494:pharmacology; D003994:Bucladesine / Q000494:pharmacology; D002417:Cattle; D002478:Cells, Cultured; D003366:Cosyntropin / Q000494:pharmacology*; D000242:Cyclic AMP / Q000378:metabolism*; D013196:Dihydrotestosterone / Q000031:analogs & derivatives / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D007213:Indomethacin / Q000494:pharmacology; D007546:Isoquinolines / Q000494:pharmacology; D007700:Kinetics; D015289:Leukotrienes / Q000494:pharmacology; D008054:Lipid Peroxides / Q000494:pharmacology; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology; D009637:Masoprocol / Q000494:pharmacology; D011284:Pregnenolone / Q000096:biosynthesis*; D013449:Sulfonamides; D013764:Tetrahydronaphthalenes / Q000494:pharmacology; D015383:Zona Fasciculata / Q000187:drug effects / Q000378:metabolism*; D015385:Zona Reticularis / Q000187:drug effects / Q000378:metabolism*
D001095:Arachidonic Acids; D016227:Benzoquinones; D004791:Enzyme Inhibitors; D007546:Isoquinolines; D015289:Leukotrienes; D008054:Lipid Peroxides; D016859:Lipoxygenase Inhibitors; D013449:Sulfonamides; D013764:Tetrahydronaphthalenes; D013196:Dihydrotestosterone; D003366:Cosyntropin; D003994:Bucladesine; C021201:12-HPETE; C025086:15-hydroperoxy-5,8,11,13-eicosatetraenoic acid; D011284:Pregnenolone; C025348:arachidonic acid 5-hydroperoxide; C001953:SU 10603; D009637:Masoprocol; C036837:2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone; D000242:Cyclic AMP; D001093:Arachidonate 15-Lipoxygenase; C009954:trilostane; C063509:N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide; D007213:Indomethacin